Therapeutically useful peptides and peptide fragments
AssigneeNorsk Hydro a.s.
InventorsGustav Gaudernack, Tobias Gedde-Dahl, Jon Amund Eriksen
Life of this patent
Estimating the term…
Abstract
Synthetic peptides and fragments of oncogene protein products which elicit T cellular immunity, for use in cancer vaccines and compositions for anti-cancer treatment.
Claims138
A method of eliciting a T cell response in a human, wherein the T cell response is specific to cancer cells expressing a mutant p21 ras oncogene protein, comprising vaccinating said human with a corresponding mutant peptide consisting of an amino acid sequence found in normal p21 ras protein (Sequence I.D. No. 57 herein) that includes at least positions 8-17 of said protein but not more than positions 1-25 of said protein, but wherein the amino acid residues at positions 12 and 13 of said sequence are not both Gly, said peptide being capable of binding to both type DQ and type DR human leucocyte antigen (HLA) molecules.
A method of stimulating the proliferation of T cells from a human patient afflicted with a type of cancer that is associated with a p21 ras oncogene, said T cells being specific to cancer cells expressing a mutant p21 ras oncogene protein, which method comprises the following steps:
- i) withdrawing peripheral blood from said human;
- ii) separating mononuclear cells from said withdrawn blood;
- and
- iii) incubating said mononuclear cells with a mutant peptide corresponding to the mutant p21 ras oncogene protein expressed by the cancer cells, said peptide having an amino acid sequence found in normal p21 ras protein (Sequence I.D. No. 57 herein) that consists of at least positions 8-17 of said protein but not more than positions 1 25 of said protein, but wherein the amino acid residues at positions 12 and 13 of said sequence are not both Gly, said peptide being capable of binding to both type DQ and type DR human leucocyte antigen (HLA) molecules.
A peptide consisting of an amino acid sequence found in normal p21 ras protein (Sequence I.D. No. 57 herein) that includes at least positions 8-17 of said protein but not more than positions 1-25 of said protein, but wherein the amino acid residues at positions 12 and 13 of said sequence are not both Gly, said peptide being capable of binding to both type DQ and type DR human leucocyte antigen (HLA) molecules.
A peptide selected from the group consisting of the peptides set forth in Sequence I.D. Nos. 80, 81, 82, 83, 84, 85, and 86 herein.
A peptide selected from the group consisting of the peptides set forth in Sequence I.D. Nos. 87 and 88 herein.
Dependencies are inferred from the claim text.